Nomogram for bretylium dosing in renal impairment.
Bretylium (Bretylol), an antiarrhythmic agent, is currently being used in the prophylaxis and treatment of patients with life-threatening ventricular fibrillation and tachycardia not responsive to conventional therapy. Because bretylium has a delayed onset of action that commonly causes hypotension and may increase ventricular irritability, its use in patients (especially patients with renal impairment) must be exercised with caution. Our results show that the maximum plasma concentration (Cmax) observed at the end of bretylium infusion, when normalized to the dose, increases significantly as renal function diminishes. Significant reductions in renal and total body clearance of bretylium have been observed in patients with renal insufficiency. In order to minimize the risk of potential toxicity following multiple dosing in such patients, dosage adjustments are necessary. Based on correlations developed between the total body clearance of bretylium and renal function, we present a nomogram herein that can be effectively used for adjusting the dosage of bretylium in patients with renal impairment.
D000328:Adult; D001949:Bretylium Compounds / Q000008:administration & dosage*; D001950:Bretylium Tosylate / Q000008:administration & dosage* / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D004334:Drug Administration Schedule; D006801:Humans; D007263:Infusions, Parenteral; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
D001949:Bretylium Compounds; D001950:Bretylium Tosylate; D003404:Creatinine